In a step towards a tetravalent dengue virus subunit vaccine which is economical to produce, highly immunogenic and stable, a hybrid dengue virus envelope (E) protein molecule has been constructed. It consists of 36 amino acids from the membrane protein, the N-terminal 288 amino acids of the dengue-2 virus E protein plus amino acids 289-424 of the dengue-3 virus E protein. It has been engineered for secretory expression by fusion to a mellitin secretory signal sequence and truncation of the hydrophobic transmembrane segment. Using the baculovirus expression system and serumfree conditions, more than 95 % of recombinant dengue-2 virus-dengue-3 virus hybrid E protein (rD2D3E) was secreted into the cell culture supernatant in a stable form with multiple features indicative of preserved conformation. The hybrid molecule reacted with a panel of dengue virus-and
Introduction
Dengue viruses (serotypes 1-4) are now endemic in most tropical countries, and are a major cause of paediatric morbidity and mortality (Monath, 1994) . Severe disease occurs most commonly, but not exclusively, following reinfection with virus serotypes not previously encountered (Morens, 1994) . Epidemiological and laboratory data suggest that subneutralizing levels of antibody may enhance infection of Fc receptor-bearing cells, resulting in more severe disease (Morens, 1994) . Other, not mutually exclusive, hypotheses suggest that it is particular combinations of antibodyindependent host factors and virus pathogenic characteristics (strain characteristics) which result in a more severe inflammatory response, haemorrhagic manifestations and shock (Monath, 1994) .
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Fax j61 7 3864 1534. e-mail helle!biosci.uq.edu.au flavivirus-specific MAbs which recognize linear or conformational epitopes on dengue virions. Human dengue virus-specific antisera also reacted with the protein. The hybrid rD2D3E protein was able to inhibit the in vitro binding of dengue-2 and dengue-3 viruses to human myelomonocytic cells, suggesting that the receptor-binding epitope(s) was preserved. Adjuvant-free immunization with the hybrid protein induced an antibody response to both dengue-2 and dengue-3 virus in outbred mice, comparable in strength to that of individual rD2E and rD3E proteins. Notably, these antibody responses were primarily of the IgG2a and IgG2b isotype. A strong dengue virus cross-reactive T cell response was also induced in the mice, suggesting that dengue virus hybrid E proteins could form the basis of an efficacious multivalent dengue virus vaccine.
The envelope (E) protein of dengue virus contains the majority of the determinants involved in attachment to, and penetration of, host cells as well as epitopes involved in neutralization (Rey et al., 1995) . Because of the similarity between the amino acid sequence (Chu et al., 1989 ; Deubel et al., 1993) and predicted structure of the E protein of flaviviruses (Rey et al., 1995) , the possibility of preparing hybrid E proteins containing antigenic determinants from two or more dengue virus serotypes was considered. Epidemiological data suggest that clinical infections in humans are rare following exposure to a third or fourth dengue virus serotype (Morens, 1994 ; Monath, 1994) , and Rhesus monkeys infected sequentially with three dengue virus serotypes did not develop a viraemia following quaternary challenge with any of the four dengue virus serotypes (Halstead et al., 1973) . Thus, broad-spectrum immunity would appear to be a desired and achievable goal for any dengue virus vaccine programme.
Intertypic chimaeric dengue viruses have been constructed in which all of the structural protein genes of dengue-4 virus were replaced with those of dengue-1, dengue-2 or dengue-3 viruses, whilst the non-structural dengue-4 virus proteins were retained (Bray & Lai, 1991 ; Chen et al., 1995) . In the case of the dengue-2 virus-dengue-4 virus chimaera, retardation of virus replication relative to either parent virus type was observed, and it was speculated that this type of virus might be more amenable to attenuation (Bray & Lai, 1991) . However, further attenuation and the safety of these hybrid viruses has not yet been reported. Megret et al. (1992) , employing recombinant fusion proteins, demonstrated that the maintenance of a topographical arrangement of discontinuous antigenic domains in the flavivirus E protein may be important for induction of neutralizing and protective antibodies. This interpretation was corroborated by the finding that most of the antigenic epitopes of the flavivirus E protein are located on ridges on the external surfaces of the molecule (Rey et al., 1995) . MAb neutralization escape mutants of flaviviruses have been used to delineate epitopes which might be involved in binding to and\or fusion of these viruses with host cell membranes. In the flaviviruses studied, regions surrounding amino acids 71-72, 128, 224-227, 270, 303-311, 333 and 402-403 appear to be important, directly or indirectly, for the binding and\or fusion of the virus to host cell membranes (Lobigs et al., 1987 ; Cecilia & Gould, 1991 ; Jiang et al., 1993 ; Lin et al., 1994) . Our own studies suggest that some of these regions (adjacent to amino acids 128, 224-227 and 333) also contain epitopes commonly recognized by antibodies from human dengue patients (Aaskov et al., 1989) . The majority of these sites\regions appear to localize in domains II and III of the crystallographic model of the flavivirus E protein (Rey et al., 1995) . It would therefore appear to be essential to ensure integrity of most or all of these regions in the design of any subunit vaccine.
The baculovirus expression system that utilizes Autographa californica nuclear polyhedrosis virus (AcNPV) has been used to obtain high-level expression of many foreign genes, including those that require proteolytic processing, glycosylation or secretion (Richardson, 1995) . The system has also been employed to produce recombinant dengue virus E protein and NS-1, which, to varying degrees, induced protective immune responses in mice (Putnak et al., 1991 ; Deubel et al., 1991 ; Delenda et al., 1994 ; Smucny et al., 1995) . Of these, only Delenda et al. (1994) described elicitation of dengue virus serotype cross-reactive antibody responses. Although an attenuated multivalent dengue virus vaccine is currently under evaluation (Bhamarapravati & Yoksan, 1989) , a similar approach using multivalent recombinant E proteins has not been reported. This is perhaps not surprising considering the level of quality control required for a four-component vaccine. In this report, we describe the generation of a recombinant dengue-2 virus-dengue-3 virus hybrid E protein (rD2D3E), expressed in a secretory baculovirus expression system, which induced strong dengue virus serotype-specific antibody responses and dengue virus cross-reactive T cell responses in outbred mice.
Methods
Cells and viruses. C6.36 Aedes albopictus mosquito cells, used for growth of dengue virus stocks, were maintained in RPMI 1640 (Gibco) supplemented with 2-5 % heat-inactivated foetal bovine serum (FBS) at 30 mC. BHK cells were used for virus neutralization assays and grown in RPMI containing 5 % FBS at 37 mC. The human myelomonocytic cell line HL60 (Harris & Ralph, 1985) and the human non-Epstein-Barr virustransformed B cell leukaemia cell line BM13674 (Baxter & Lavin, 1992) were maintained in RPMI containing 10 % FBS supplemented with 25 mM glutamine. Spodoptera frugiperda clone 21 (Sf21) cells were employed for growth of baculoviruses as described in detail below. The baculovirus (AcNPV) used throughout was strain AcBac6. Dengue-2 virus [prototype strain New Guinea C (NGC) ; GenBank accession no. D00346], dengue-1 virus (prototype Hawaii) and dengue-4 virus (prototype H241) were originally obtained from Yale Arbovirus Reference Center, and had been passaged in both suckling mice by intracerebral inoculation and in tissue culture in C6.36 cells. Dengue-3 virus (strain 1327, Tahiti-65 ; GenBank accession no. L11439) was generously provided by the Center for Disease Control, Atlanta, GA, USA, and upon receipt was passaged twice in C6.36 cells before use for RNA isolation (see below). For production of semi-pure dengue virus preparations, virus was grown in C6.36 cells under serum-free conditions. Following clarification of the culture supernatants (14 300 g for 35 min), the virus was pelleted by centrifugation at 15 000 g for 16-18 h at 4 mC. The virus was resuspended in either TNE buffer (10 mM Tris-HCl pH 7n5 ; 100 mM NaCl ; 1 mM EDTA) or RPMI and stored in 1 ml aliquots at k70 mC. Since dengue-3 virus strain 1327 is non-cytopathic, all viruses were quantified by haemagglutination assay, where the number of virus particles equals the number of red blood cells in the reaction mixture (Schlesinger, 1977) .
Cloning of the hybrid rD2D3E protein and truncated rD2E and rD3E protein genes. Virus RNA was isolated from the supernatants of C6.36 cultures infected with dengue-2 virus and dengue-3 virus by the guanidinium isothiocyanate method, and reverse transcribed to cDNA using random hexamer primers and avian myeloblastosis virus reverse transcriptase (Amersham) (BielefeldtOhmann et al., 1994) . The cDNA was amplified by PCR using primers which included unique endonuclease restriction sites for both the joining site of the two E protein genes (EcoRI) and for cloning into the baculovirus transfer vectors (XmaI at the 5h end of the dengue-2 virus cDNA and a BglII site at the 3h end of the dengue-3 virus cDNA, respectively), as well as a stop codon at the 3h end of the dengue-3 virus gene (D2 sense, 5h ATCCCGGGTCCAGGCTTTACCATAATG 3h ; D2 antisense, 5h GGAATTCCATCCTCAGCCTGCAC 3h ; D3 sense, 5h GGAATTCCTGGAACTCAAGGGGATG 3h ; D3 antisense, 5h GTAGATCTCAACCCACTGACCCAAAG 3h). The EcoRI site was chosen to minimize alterations to the predicted secondary structure and hydrophilicity of the E protein in the joining region. The two PCR products were cloned individually into pGem-5Zf(j) shuttle T-vectors (Promega) and subsequently joined at the EcoRI site and subcloned into the baculovirus transfer vectors pMbac and pPbac (Stratagene), containing the mellitin and the human placenta alkaline phosphatase secretory signals, respectively (Mroczkowski et al., 1994) . Truncated rD2E and rD3E protein genes, encompassing nucleotides 733-2074 and 672-2115, respectively, were cloned in a similar manner into pMbac, following initial cloning into the shuttle vector pGem by TA cloning of PCR products generated as above using the following primers : D2 sense, as above ; D2 antisense, 5h GGAATTCACAGGACATCTCAAGTGC 3h ; D3 sense, 5h ATCCCGGGTTGGATGTCGGCTGAAGGA 3h ; D3 antisense, as above. The further truncation of the rD2E protein gene as well as the inclusion of additional prM sequence in the rD3E construct were dictated by the constraints on PCR primer design using the OLIGO program. Construction integrity was verified by DNA sequencing using dye terminators, cycle sequencing reactions and automated sequence analysis (ABI Systems).
Transfection and selection of recombinant viruses. Using the pMbac-D2D3E, pPbac-D2D3E, pMbac-D2E and pMbac-D3E plasmids, Sf21 cells were co-transfected with linearized AcPak6 DNA (ClonTech) using 25 ng baculovirus DNA and approximately 500 ng plasmid DNA per transfection. The DNAs were mixed with liposomes (ClonTech) and after a 15 min incubation were added to serum-free confluent monolayers of Sf21 cells in 10 cm# tissue culture plates. Following an overnight incubation in serum-free TC100 medium (Gibco), the cultures were supplemented with TC100 medium containing 5 % FBS and incubated for a further 48 h. The medium was then collected and replaced with fresh medium. The cultures were incubated for a further 24 h, after which the medium was collected and the cells stained with X-Gal (0n03 %, w\v) to assess the level of recombinant virus replication. The two batches of culture media collected were employed separately for plaque purification of recombinant virus, which was performed according to published protocols (O'Reilly et al., 1994) except that incubations were for 4-5 days. At this stage, X-Gal was applied to the cultures, and after a further overnight incubation, blue plaques were picked and resuspended in 500 µl TC100 medium containing 10 % serum. One hundred µl of this sample was adsorbed to 4i10& Sf21 cells in 2n5 cm# tissue culture wells, and the cell cultures were incubated for 4 days. The culture supernatant was then collected and subjected to a second round of plaque purification. Following each round of clone expansion, 80 µl of clarified culture medium was blotted onto nitrocellulose and the dot blots were immunolabelled with a flavivirus E protein-specific, conformationdependent MAb, 4G2 (Gentry et al., 1982) , as described below, to confirm the presence of immunoreactive dengue virus E protein.
Preparative production of recombinant proteins. Confluent monolayers of Sf21 cells in 150 cm# tissue culture flasks were inoculated with the recombinant or wild-type baculoviruses at an m.o.i. 5 in less than 5 ml medium. Adsorption was allowed to proceed for 2 h, and was followed by addition of 40-50 ml serum-free medium [either ExCell%!! (CSL) or Protein-Free Medium (Pharmingen)]. The conditioned medium was collected after 48 h (see Results) and the proteins were precipitated with a final concentration of 9 % sterile polyethylene glycol 6000 (PEG ; BDH) by overnight incubation with stirring at 4 mC. The precipitates were pelleted by centrifugation (6 h at 14 300 g) and resuspended in sterile TNE buffer. The proteins were stored at k20 mC, without addition of proteinase inhibitors, until use.
SDS-PAGE, electroblotting and immunodetection by enhanced chemiluminescence (ECL).
The recombinant dengue virus proteins and proteins from virions were separated on non-reducing 10 or 15 % SDS-PAGE gels (with 5 % stacking gels) and transferred to nitrocellulose membranes by electroblotting in methanol-Tris-glycine buffer, followed by blocking for 48 h with ECL blocking buffer (Staton et al., 1995) . The membranes were incubated with primary antibodies [either dengue virus-specific MAbs (see Table 1 ) or human or murine sera], diluted in Tris-buffered saline (TBS) (pH 7n4) containing 0n1% Tween 20, 1 mg\ml BSA, 1 mg\ml non-fat skim milk powder and 1 % FBS, for 2 h at room temperature, followed by 3i15 min washes in TBS containing 0n1 % Tween 20. This was followed by a 1 h incubation with horseradish peroxidase-conjugated rabbit anti-mouse or anti-human immunoglobulin antibody (Dakopatts), or in the case of isotyping studies, with isotype-specific goat anti-mouse IgM, IgG1, IgG2a, IgG2b or IgG3 (The Binding Site). Bound antibody was visualized by ECL (reagents and films from Amersham) as described by Staton et al. (1995) . Unless otherwise indicated, the results shown are from the first 50-60 s exposure.
Analysis of glycosylation of recombinant dengue virus E proteins. The effect of endoglycosidase F and H (both from Boehringer Mannheim) on the recombinant E proteins was assessed as described by O'Reilly et al. (1994) . Briefly, PEG-precipitated rD2D3E, rD2E or rD3E or the corresponding cell lysates were incubated with either endoglycosidase F in 20 mM sodium phosphate (pH 7n2) containing 2 % (v\v) NP40 and 10 mM EDTA, or endoglycosidase H in 100 mM sodium citrate (pH 5n5) (all final concentrations). Enzymes were omitted from the control samples. Following incubation at 37 mC for 20-24 h, the proteins were separated on 8, 10 or 15 % polyacrylamide gels, electroblotted, immunolabelled with MAb 4G2 and visualized as described above. Alternatively, the lectin-binding properties of the recombinant E proteins, with or without prior endoglycosidase treatment, were examined by a protocol modified from Seto et al. (1995) . Proteins transferred onto nitrocellulose membranes by electroblotting were reacted with different dilutions of biotinylated lectins (Datura stramonium, Galanthus nivalis, Maackia amurensis II and concanavalin A ; all from Vector Laboratories), followed by incubation with horseradish peroxidase-conjugated streptavidin (Boehringer Mannheim) and visualization of binding by ECL.
ELISA. Flexible PVP 96-well ELISA plates (Dynatech) were coated overnight at 4 mC with rD2D3E protein or dengue virus diluted in borate-saline buffer (pH 9n0). Following blocking for 60 min at 23 mC with 5 % KPL milk diluent (Kirkegaard & Perry Laboratories) and two washes in PBS containing 0n05 % Tween 20 (PBST), primary antibodies (MAbs or polyclonal sera) at appropriate dilutions in PBST containing 5 % KPL milk diluent were applied and incubation was continued for 45 min at 23 mC. After four washes in PBST, horseradish peroxidaseconjugated anti-mouse immunoglobulin (Dakopatts) diluted in PBST containing 5 % KPL milk diluent was added to the wells. Following incubation for 45 min at 23 mC, the plates were washed four times with PBST and four times in PBS, followed by application of ophenylenediamine substrate (Sigma). After addition of 3 M HCl, the A %*! was read on a Dynatech MR5000 plate reader.
Virus-binding blocking. To demonstrate blocking of dengue virus binding to HL60 and BM cells by rD2D3E, washed and pre-cooled (4 mC) cells were pre-incubated for 2 h with either media control or PEGprecipitated proteins from wild-type baculovirus-infected culture supernatant or the rD2D3E protein (10 µg per 10' cells). This was followed by incubation of the cells with semi-pure dengue-2 or dengue-3 virus, at a cell to particle ratio of 1 : 5i10'k1:1i10(, for 90 min. All incubations were at 4 mC. Following extensive washing of the cells, total RNA was extracted as described above, and the relative levels of virus binding were assessed by RT-PCR using primers for either the prM protein gene (D2 sense, 5h ATGGCGTTCCATTTAACCACACGTA 3h ; D2 antisense, 5h CATTGAAGGAGCGACAGC 3h ; D3 sense, 5h ACTTGACTTCA-CGAGATGGAGA 3h ; D3 antisense, 5h CCACTCCCACGCATCT-CATTGT 3h) or the transmembrane part (D2 sense, 5h TAGAA-GCAGAACCTCCAT 3h ; D2 antisense, 5h GAGCACCATAACTC-CCAAAT 3h ; D3 sense, 5h TTGTGATTGGAACTGGAG 3h ; D3 antisense, 5h CACCACAGCTCCTAGAT 3h) of the dengue-2 and dengue-3 virus E protein genes, respectively. Using 28 cycles of amplification, approximately 5n8i10% virus particles in a reaction with 10' cells could be detected. Primers for human β-actin were included in the PCR reaction for sample equalization (Bielefeldt-Ohmann et al., 1994) . This allowed semi-quantitative comparison of virus binding to target cells with or without pre-incubation with rD2D3E protein or controls following densitometric analysis using an ImageQuant densitometer and Jianmin et al. (1995) . † † Human post-primary dengue virus infection sera, collected in Queensland. , Not done.
software (Molecular Dynamics) as described previously (BielefeldtOhmann et al., 1994) .
Immunization of mice. Groups of four mice (female outbred Quackenbush ; Animal Resources Centre, Murdoch, Western Australia) were immunized by the intraperitoneal (i.p.) or intramuscular (i.m.) route with approximately 10 µg PEG-precipitated rD2D3E, rD2E or rD3E in TNE (the concentration was determined by comparison to purified histidine-tagged rD2E in a dot-blot titration ; not shown), or one of the four dengue viruses (live in serum-free RPMI) in amounts equalized with respect to the E protein, as determined by 4G2 reactivity in a dot-blot titration and corresponding to approximately 4i10& virus particles (infectious, non-infectious and incomplete ; Schlesinger, 1977) . The mice received three injections, at days 0, 14 and 42, and were bled on days 28, 56 and 72 or 90. The sera recovered were subsequently tested by Western blotting and neutralization assays. All animal experiments were conducted with institutional ethics approval in accordance with the National Health and Medical Research Council Guidelines for Experiments in Animals.
Virus neutralization assay. Sera collected from immunized mice were assayed by a plaque reduction neutralization test (Aaskov et al., 1988) . Briefly, 1 : 20 dilutions of pools of heat-inactivated serum from groups of mice immunized in the same manner were mixed with 10-fold dilutions of dengue-2 virus (NGC) or dengue-3 virus (strain PRS225489) prior to addition of BHK cells. After 7 days incubation, the cells were stained with 0n5 % crystal violet and plaques were counted. Antibody titre was expressed as a neutralization index : log "! l (p.f.u. virus alone)\(p.f.u. virus j antibody).
In vitro lymphocyte stimulation and IL-3 assay. Animals were terminated 48 days after the third vaccination and spleen cells were isolated as described by Bielefeldt-Ohmann et al. (1994) . Triplicate cultures of 1i10& cells in RPMI containing 5 % FBS, in round-bottomed microculture wells (Nunc), were incubated with or without a dose range (approximately 0n3-2n3i10# virus particles per cell) of semi-pure dengue-2, dengue-3 or dengue-4 virus for 5 days at 37 mC in 5% CO # in air. The culture supernatants were then collected and tested for IL-3 bioactivity using the FDC-P1 reporter cell line, as described by Fitzpatrick & Kelso (1995) .
Results

Construction of a hybrid rD2D3E protein gene, expression in the baculovirus expression system, and biochemical features
Using the cloning strategy described in Methods and illustrated in Fig. 1 , a hybrid molecule encoded by nucleotides 733-1709 from the dengue-2 virus genome and nucleotides 1710-2115 from the dengue-3 virus genome was generated. This approach introduced two amino acid changes at the joining site : from DK in both of the native dengue-2 virus and dengue-3 virus E proteins to EF in the hybrid protein (Fig. 1) . This change did not alter the predicted secondary structure and hydrophilicity of the protein, as assessed by six algorithms using the GCG program suite (University of Wisconsin), and is within the range of inter-and intratypic amino acid variations seen in this region of the protein (Lanciotti et al., 1994) . Furthermore, a search of both GenBank and the SWISS-PROT databases failed to demonstrate homology of the newly created sequence with any known human protein sequences. The integrity of the hybrid gene was affirmed by DNA sequencing.
Spodoptera cells infected with recombinant baculovirus containing the mellitin secretory signal produced and secreted more recombinant protein more quickly than recombinant virus containing the alkaline phosphatase secretory signal. However, in both cases, maximum secretion, in excess of 250 µg recombinant protein per 10' cells, was obtained 48-72 h post-infection, with 95 % of the protein secreted during the first 48-56 h. After that time, increasing cell death correlated with intracellular retention of recombinant protein.
The hybrid protein mainly occurred as monomers with an apparent molecular mass of 48-49 kDa on non-reducing gels. Low levels of rD2D3E dimerization could be detected by immunoblotting using MAb 4G2 following protein separation under the same gel conditions. Endoglycosidase F treatment of rD2D3E slightly increased the mobility of the protein compared to the undigested control, indicating glycosylation ( Fig. 2) . The molecular mass of the digested protein was approximately 47-48 kDa. These changes are comparable to those found for dengue-2 virus grown in insect cells (Johnson et al., 1994) and for recombinant dengue virus proteins (Deubel et al., 1991) . Endoglycosidase H had no detectable effect on the mobility of either intracellular or secreted protein ( Fig. 2 and data not shown). Concanavalin A, Galanthus nivalis and Maackia amurensis II, but not Datura stramonium, bound to the rD2D3E protein, suggesting the presence of mannose residues in high-mannose and\or hybrid oligosaccharide chains and sialic acid residues, but no complex or hybrid N-glycan structures ( Fig. 2 and data not shown).
Antigenicity and functional activity of the hybrid rD2D3E protein
The antigenic properties of the hybrid rD2D3E proteins were analysed using MAbs raised against dengue virus serotypes 1-4 and against other flaviviruses, and assessed by Western blotting and solid-phase ELISA. An abridged summary of the results is given in Table 1 ; the preservation of both conformation-dependent and\or cross-reactive determinants on the hybrid E protein is demonstrated. The lack of reactivity with MAb 3H5 is consistent with its specificity for an epitope in domain III of dengue-2 virus (Trirawatanapong et al., 1992) . This domain in the hybrid is derived from dengue-3 virus. In contrast, the interesting reactivity of MAbs 128 and 234, reportedly specific for dengue-2 virus, may be due to hitherto unknown cross-reactivities with the dengue-3 virus strain used here. Sera obtained from human dengue fever patients (primary infections) also reacted with the recombinant hybrid protein in Western blot experiments (Table 1) . Pre-incubation of the human myelomonocytic cell line HL60 or the human B cell line BM13674 with rD2D3E protein inhibited, in a specific manner, subsequent binding of both dengue-2 and dengue-3 viruses. Densitometric assessment, using equalization with respect to the β-actin signal, demonstrated a reduction of 38 % of dengue-2 or dengue-3 virus binding following pre-incubation of the cells with rD2D3E ( Fig. 3 and data not shown). This is a notable level of inhibition considering the primarily monomeric nature of the recombinant E protein and the highly multimeric occurrence of the E protein on virions (Rey et al., 1995) .
Immunogenicity of the rD2D3E protein
Groups of four outbred mice were immunized three times, by the i.p. or i.m. route, with approximately 10 µg adjuvantfree rD2D3E, rD2E or rD3E in TNE. The animals were bled 2 weeks after the second and third vaccinations, as well as at the termination of the experiment (day 90), and the sera were pooled and tested for reactivity with all four dengue virus serotypes in Western blot experiments (at final dilutions of 1 : 75), as well as for dengue-2 and dengue-3 virus neutralizing activity. A strong antibody response against both dengue-2 and dengue-3 virus E proteins was detected 2 weeks following the third vaccination, but no or only minimal cross-reactivity with dengue-1 and dengue-4 virus was detected (Fig. 4 and data not shown). Significant levels of antibody specific for dengue-3 virus were present after the second vaccination, with a further increase after the third vaccination, whereas notable levels of dengue-2 virus-specific antibodies were seen only after the third vaccination, and then only in the group receiving rD2D3E i.p. (Fig. 4 and data not shown) . Significantly, however, the virus-specific antibodies were primarily of the IgG2a and IgG2b isotypes, with some additional anti-dengue-3 virus-specific activity of the IgM and IgG1 isotypes (Fig. 4) .
In order to compare the immune response to the hybrid rD2D3E protein with that induced by live virus, groups of four Quackenbush mice were vaccinated with one of the three recombinant proteins (in the same amounts as in the previous experiment) or with semi-pure dengue-1, dengue-2, dengue-3
. Murine immunoglobulin subclass responses specific for (a) dengue-2 and (b) dengue-3 virus following adjuvantfree immunization with hybrid rD2D3E protein, rD2E protein or rD3E protein, or dengue-1, dengue-2, dengue-3 or dengue-4 virus. Pooled sera from each group bled 2 weeks after the third vaccination were tested at a final dilution of 1 : 75, and ECL films were exposed for 50-60 s. Groups : 1, rD2D3E ; 2, rD3E ; 3, rD2E ; 4, 5, 6, 7, 8, TNE buffer or dengue-4 virus (the latter in amounts equalized to the recombinant proteins with respect to levels of native E protein). Vaccination was by the i.p. route, using the same vaccination schedule, and again no adjuvant was used. The results confirmed those of the previous experiment, i.e. strong antibody responses to dengue-2 and dengue-3 viruses, mainly of the IgG2a and IgG2b isotypes, were obtained with the hybrid rD2D3E protein, as well as with the rD2E and rD3E proteins, respectively (Fig. 5) . Furthermore, the hybrid protein appeared to induce a response comparable to that of live dengue-2 and dengue-3 viruses, with low but detectable crossreactivity to dengue-1 and dengue-4 viruses (data not shown). A dose titration experiment in which groups of four mice received three i.p. adjuvant-free vaccinations with 0n1, 1n0, 10n0 or 50 µg rD2D3E or TNE demonstrated that the antibody response reached a plateau at 10 µg per animal per dose. In both the former experiments, 1 log or more of neutralizing activity was detected against dengue-2 but not dengue-3 virus in animals immunized with the hybrid protein by the i.p. route, as well as in animals immunized with rD2E Fig. 6 . Dengue-2 virus neutralizing antibody activity induced by adjuvantfree vaccination with hybrid rD2D3E protein, truncated rD2E protein or rD3E protein or with live dengue viruses. Pooled sera (four animals per group), obtained 2 weeks after the third vaccination, were tested at a final concentration of 1 : 20 in a plaque reduction assay (see Methods). Data are presented as neutralization indices, with 1 significant. In experiment 2, all vaccinations were by the i.p. route. Fig. 7 . Cross-reactive in vitro T lymphocyte responses (IL-3 production) induced by adjuvant-free immunization of mice with hybrid rD2D3E protein, rD2E protein or rD3E protein. Mice were terminated 6 weeks following the third i.p. vaccination (groups 1, 3 and 5 in Fig. 6 , as well as the TNE buffer control group) and purified spleen cells were stimulated in vitro for 5 days with a dose range of semi-pure dengue-2 ($), dengue-3 (>) or dengue-4 () virus, followed by bioassay for IL-3 activity. Each data-point represents values obtained for individual mice with the optimal virus concentration (in this experiment approx. 10 haemagglutination units per 10 5 cells at the start of culture).
protein or dengue-2 virus (Fig. 6) , whereas neither the hybrid molecule, rD3E nor dengue-3 virus induced antibodies with detectable neutralizing activity under the test conditions employed here (data not shown). Furthermore, the hybrid rD2D3E protein induced a strong dengue virus cross-reactive T cell response as evidenced by IL-3 production in response to in vitro dengue virus stimulation, with levels in immunized mice ranging from 10-to 1000-fold those seen in control mice (Fig. 7) .
Discussion
This study demonstrates that a hybrid molecule consisting of the N-terminal two-thirds of the dengue-2 virus E protein and a truncated C-terminal one-third of dengue-3 virus, corresponding to domain I-II and domain III, respectively, of the tick-borne encephalitis virus E protein model (Rey et al., 1995) , can be secreted from baculovirus-infected insect cells in an antigenic form with high conformational integrity. The site of the junction between the dengue-2 virus and the dengue-3 virus portions of this E protein was chosen so as not to disrupt disulfide bridges (Lin et al., 1994) or change the predicted hydrophilic characteristics of the native proteins. Both dengue-2 and dengue-3 virus-specific epitopes as well as dengue virus and flavivirus cross-reactive epitopes were preserved on the hybrid molecule (Table 1) . Although the majority of the hybrid molecules occurred as monomers, the rD2D3E protein could still interfere with the binding to (Fig. 3) , and subsequent infection of (unpublished data), several cell types by dengue-2 and dengue-3 viruses, suggesting that functional epitopes are preserved.
The hybrid protein induced a strong antibody response in outbred mice, with the majority of the anti-dengue-2 and antidengue-3 virus-specific antibodies being of the IgG2a and IgG2b isotype. This latter finding is significant in light of a recent report by Smucny et al. (1995) that recombinant baculovirus-derived dengue-2 virus E protein preferentially induced an IgG1 response, in contrast to the dengue-2 virus, which preferentially induced IgG2a. The reason for the discrepancy between the results of Smucny et al. (1995) and those of the present study is not entirely clear, but three possibilities could be considered. Firstly, the strain of mice used and secondly the age of the animals are both factors known to influence the murine antibody response due to biased T helper cell stimulation (Barrios et al., 1996 ; Hocart et al., 1989) . Thirdly, there is increasing evidence to suggest that the dose of antigen, perhaps more than any other single factor, influences the cytokine profile of both naı$ ve (primary response) and differentiated (secondary response) T cells (Bretscher et al., 1992 ; Constant et al., 1995 ; Hosken et al., 1995) , and thus, through cognate B cell-T cell interactions, the regulation of immunoglobulin isotype synthesis, including levels and specificities (Coffman et al., 1993) . Since most currently available reports on recombinant dengue virus E protein vaccines lack exact data on doses used, this aspect will have to await more definite comparisons. In our preliminary assessments of the T lymphocyte response in animals vaccinated with the rD2D3E protein, a strong dengue virus cross-reactive secondary in vitro IL-3 response was induced, suggesting preservation of T cell epitopes on the rD2D3E protein Kulkarni et al., 1992) . It is notable that IL-3 production is closely correlated with IFN-γ production (Maraskovsky et al., 1992) , a finding corroborated by testing a selected set of samples for IFN-γ from the experiment reported here (H. Bielefeldt-Ohmann, unpublished data). IFN-γ is considered to be the main factor regulating the isotype switch from IgM to IgG2a production in mice (Coffman et al., 1993) .
The present results suggest that induction of IgG2a production is in itself not necessarily commensurate with virus neutralization, but the lack of in vitro neutralizing antibody activity does not preclude in vivo protection against virus challenge (Levine et al., 1991) . Unfortunately, the current murine model used for dengue virus protection studies, i.e. challenge of very young mice by the intracerebral route, may be inappropriate for revealing the true potential of this and previously described subunit dengue virus vaccines (Aaskov et al., 1988 ; Delenda et al., 1994) . Susceptibility of mice to intracerebral dengue virus challenge is age-dependent, and immunization must therefore be initiated at a time when the immune system is still immature (Sarzotti et al., 1996 ; Barrios et al., 1996) . Furthermore, the effector mechanisms required for protection of brain tissue may have little relevance to the effector mechanisms required for protection of humans against a mosquito-borne infection. Finally, challenge studies following immunization with the candidate rD2D3E protein vaccine have not been conducted due to the ethical problems associated with the intracerebral challenge model.
Although not yet studied in detail, the results depicted in Table 1 and Figs 4 and 5 suggest that the anti-dengue-2 and anti-dengue-3 virus antibody responses may be directed against different epitopes on the E protein, and also that neither part of the hybrid molecule significantly interferes with the response to the other part. These may thus constitute important factors in the overall safety of a human vaccine based on hybrid E proteins, in light of (i) the limited antibody cross-reactivity to dengue-1 and dengue-4 viruses induced by rD2D3E, (ii) the fact that the human antibody response to dengue viruses is directed towards multiple disparate epitopes on the E protein (Aaskov et al., 1989 ; Innis et al., 1989) and (iii) antibody-mediated infection enhancement of Fc receptorbearing cells is mainly or solely due to flavivirus cross-reactive determinants (Brandt et al., 1982 ; Morens, 1994) .
The approach taken in this study offers several advantages over most systems so far reported for baculovirus-produced dengue virus E proteins : (i) greater stability of the secreted protein compared to protein accumulating intracellularly (unpublished data), (ii) easier purification, and thus (iii) relatively higher yields (amounts exceeding 250 µg per 10' cells) (Staropoli et al., 1996 ; Delenda et al., 1994 ; Richardson, 1995) . In contrast to the original report on the baculovirus transfer vectors used in this study (Mroczkowski et al., 1994) , higher yields of recombinant protein were consistently obtained with the mellitin construct than with the alkaline phosphatase construct. The present study has demonstrated that it is possible to construct a hybrid E protein which not only retains native tertiary structure and functional qualities in the form of putative receptor binding, but is also a strong immunogen, inducing B cell and T cell responses to the two dengue viruses constituting the hybrid and, at the T helper cell level, to the dengue virus serotypes not included in the construct. This suggests that a tetravalent dengue virus vaccine could be based on two components, a rD2D3E and a rD1D4E protein, thereby reducing the amount of safety and quality control, as well as preliminary assessment required, compared to a vaccine constituting four individually produced molecules.
